About: Gold nanoparticle‐adjuvanted S protein induces a strong antigen‐specific IgG response against severe acute respiratory syndrome‐related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gold nanoparticle‐adjuvanted S protein induces a strong antigen‐specific IgG response against severe acute respiratory syndrome‐related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Gold nanoparticle‐adjuvanted S protein induces a strong antigen‐specific IgG response against severe acute respiratory syndrome‐related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs
Creator	Tani, Hideki Kataoka, Michiyo Hasegawa, Hideki Iwata-Yoshikawa, Naoko Sekimukai, Hanako Arai, Katsuhiko Niikura, Kenichi Fukushi, \| Hideki, \| Noriyo Nagata, \| Suzuki, \|
source	Medline; PMC
abstract	The spike (S) protein of coronavirus, which binds to cellular receptors and mediates membrane fusion for cell entry, is a candidate vaccine target for blocking coronavirus infection. However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS‐CoV) induces a lung eosinophilic immunopathology upon infection. The present study evaluated two kinds of vaccine adjuvants for use with recombinant S protein: gold nanoparticles (AuNPs), which are expected to function as both an antigen carrier and an adjuvant in immunization; and Toll‐like receptor (TLR) agonists, which have previously been shown to be an effective adjuvant in an ultraviolet‐inactivated SARS‐CoV vaccine. All the mice immunized with more than 0.5 µg S protein without adjuvant escaped from SARS after infection with mouse‐adapted SARS‐CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice. The AuNP‐adjuvanted protein induced a strong IgG response but failed to improve vaccine efficacy or to reduce eosinophilic infiltration because of highly allergic inflammatory responses. Whereas similar virus titers were observed in the control animals and the animals immunized with S protein with or without AuNPs, Type 1 interferon and pro‐inflammatory responses were moderate in the mice treated with S protein with and without AuNPs. On the other hand, the TLR agonist‐adjuvanted vaccine induced highly protective antibodies without eosinophilic infiltrations, as well as Th1/17 cytokine responses. The findings of this study will support the development of vaccines against severe pneumonia‐associated coronaviruses.
has issue date	2019-11-18(xsd:dateTime)
bibo:doi	10.1111/1348-0421.12754
bibo:pmid	31692019
has license	no-cc
sha1sum (hex)	5f1985c2a2b2dbb9c75d9197d0d4a83186579711
schema:url	https://doi.org/10.1111/1348-0421.12754
resource representing a document's title	Gold nanoparticle‐adjuvanted S protein induces a strong antigen‐specific IgG response against severe acute respiratory syndrome‐related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs
has PubMed Central identifier	PMC7168429
has PubMed identifier	31692019
schema:publication	Microbiol Immunol
resource representing a document's body	covid:5f1985c2a2b2dbb9c75d9197d0d4a83186579711#body_text
is schema:about of	named entity 'immunization' named entity 'adjuvants' named entity 'SARS-CoV' named entity 'carrier' named entity 'study' named entity 'immunization' named entity 'mice' named entity 'THE LUNGS' named entity 'CANDIDATE' named entity 'EOSINOPHILIC' named entity 'MOUSE' named entity 'immunopathology' named entity 'mediates' named entity 'SARS-CoV' named entity 'kinds' named entity 'vaccine' named entity 'SARS-CoV' named entity 'eosinophilic' named entity 'induces' named entity 'eosinophilic' named entity 'cell' named entity 'induces' named entity 'fails' named entity 'mice' named entity 'recombinant' named entity 'SARS-CoV' named entity 'protective antibodies' named entity 'lungs' named entity 'lungs' named entity 'bronchiole' named entity 'immunoreactive' named entity 'immunization' named entity 'Thermo Fisher Scientific' named entity 'formalin' named entity 'adjuvant' named entity 'protein' named entity 'Type 1 interferon' named entity 'protein' named entity 'protein' named entity 'Fujifilm' named entity 'immunization' named entity 'vaccine' named entity 'IL-5' named entity 'blood vessels' named entity 'homogenates' named entity 'CD26' named entity 'chemokines' named entity 'transmission electron microscopy' named entity 'Serum samples' named entity 'bronchioles' named entity 'Qiagen' named entity 'coronaviruses' named entity 'immune responses' named entity 'protein' named entity 'Tris-buffered saline' named entity 'lungs' named entity 'antigens' named entity 'immunization' named entity 'severe acute respiratory syndrome coronavirus' named entity 'eosinophilic' named entity 'protein binding' named entity 'infection' named entity 'Japan' named entity 'respiratory syncytial virus' named entity 'adjuvanted' named entity 'infection' named entity 'gene' named entity 'RANTES' named entity 'T-cell' named entity 'macrophages' named entity 'IFN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software